Supplementary figure 1. Concentration-effect curve for dupilumab level and ΔEASI at 24 weeks in patients with a moderate-to-severe baseline EASI (≥6.0).

Concentration-effect curve for patients with a moderate-to-severe baseline EASI (≥6.0) showing the dupilumab serum level in μg/mL at 24 weeks on the x-axis and correlating ΔEASI at 24 weeks (versus baseline) on the y-axis. All patients were sorted from low to high drug concentration, with each dot representing the mean concentration with SDs and correlating ΔEASI for 10 patients (last group 9 patients).

本数据集展示了中度至重度基线 EASI（≥6.0）患者群体中，dupilumab 血清浓度在 μg/mL 单位下的浓度-效应曲线，横轴表示第 24 周时的血清浓度，纵轴则反映了与基线相比的第 24 周EASI 变化值。所有患者按药物浓度由低至高进行排序，每个点代表 10 名患者（最后组别为 9 名患者）的平均浓度及其相应的 EASI 变化值。